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ABSTRACT
Cytochrome P450 (CYP)2C9 and CYP2C19 are important hu-
man enzymes that metabolize therapeutic drugs, environmental
chemicals, and physiologically important endogenous com-
pounds. Initial studies using primary human hepatocytes showed
induction of both the CYP2C9 and CYP2C19 genes by tert-
butylhydroquinone (tBHQ). As a pro-oxidant, tBHQ regulates the
expression of cytoprotective genes by activation of redox-sensing
transcription factors, such as the nuclear factor E2-related factor
2 (Nrf2) and members of the activator protein 1 (AP-1) family of
proteins. The promoter region of CYP2C9 contains two putative
AP-1 sites (TGAGTCA) at positions 22201 and 21930, which are
also highly conserved in CYP2C19. The CYP2C9 promoter is
activated by ectopic expression of cFos and JunD, whereas Nrf2
had no effect. Using specific kinase inhibitors for mitogen-activated
protein kinase, we showed that extracellular signal-regulated
kinase and Jun N-terminal kinase are essential for tBHQ-
induced expression of CYP2C9. Electrophoretic mobility shift
assays demonstrate that cFos distinctly interacts with the dis-
tal AP-1 site and JunD with the proximal site. Because cFos
regulates target genes as heterodimers with Jun proteins, we
hypothesized that DNA looping might be required to bring the
distal and proximal AP-1 sites together to activate the CYP2C9
promoter. Chromosome conformation capture analyses con-
firmed the formation of a DNA loop in the CYP2C9 promoter,
possibly allowing interaction between cFos at the distal site and
JunD at the proximal site to activate CYP2C9 transcription in
response to electrophiles. These results indicate that oxidative
stress generated by exposure to electrophilic xenobiotics and
metabolites induces the expression of CYP2C9 and CYP2C19 in
human hepatocytes.
Introduction
There are four cytochrome P450 (CYP)2C genes in humans, as
follows: CYP2C9, CYP2C8, CYP2C19, and CYP2C18 (Goldstein
and de Morais, 1994). CYP2C9 and CYP2C19 enzymes metab-
olize ∼20% of clinically prescribed drugs and a number of en-
vironmental chemicals and are found primarily in human liver
(Zanger and Schwab, 2013). CYP2C19 metabolizes the anticon-
vulsant drug S-mephenytoin, proton pump antiulcer drugs such
as omeprazole, theb-adrenergic receptor blocker propranolol, the
anxiolytic diazepam, and clopidigrel, used to prevent heart
attacks and strokes (Zanger and Schwab, 2013). CYP2C9 is the
most abundant of the CYP2C enzymes in human liver, and its
substrates include the anticoagulant warfarin, the hypoglycemic
drugs tolbutamide and glipizide, the anticonvulsant phenytoin,
the anticancer drug cyclophosphamide, the angiotensin II blocker
losartan, the diuretic torsemide, and numerous nonsteroidal anti-
inflammatory drugs, such as diclofenac, flurbiprofen, ibuprofen,
piroxicam, andmefenamic acid (Goldstein, 2001; Lee et al., 2002).
CYP2C9 also metabolizes the endogenous substrate arachidonic
acid to the biologically active and vasoactive epoxyeicosatrienoic
acids (Fisslthaler et al., 1999).
TheCYP2C genes are induced by drugs and xenobiotics, such
as rifampicin, St. John’s wort, phenytoin, phenobarbital, and
dexamethasone (Gerbal-Chaloin et al., 2001; Gerbal-Chaloin
et al., 2002; Chen et al., 2004), leading to enhanced metabolism
of many therapeutic drugs and other CYP2C substrates (Rettie
and Jones, 2005). This can alter drug efficacy, resulting in
tolerance and drug-drug interactions. There is considerable
interindividual variability in CYP2C9/CYP2C19 expression
and in metabolism of their substrates partly due to genetic
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polymorphisms and partly due to prior exposure of humans to
drugs capable of inducing these enzymes. Studies in humans
have reported enhanced clearance of drugs, such as tolbuta-
mide, phenytoin, glyburide, and glipizide after treatment with
rifampicin (Zilly et al., 1975; Kay et al., 1985; Niemi et al., 2001).
The induction of CYP2C9 by xenobiotics is mediated by three
major xenobiotic-sensing nuclear receptors, as follows: the con-
stitutive androstane receptor, the glucocorticoid receptor, and
the pregnane X receptor (PXR). The activation of these nu-
clear receptors by xenobiotics induces CYP2C9 transcription
by binding to cis-regulatory elements on the promoter of
CYP2C9 gene. Regulatory elements identified in the promoter
of CYP2C9 include proximal HNF4a binding sites located at
2152, 2185, and 2211; a glucocorticoid-responsive element
at 21675; and proximal and distal constitutive androstane
receptor/PXR response elements at positions 21839 and 22899,
respectively (Ibeanu and Goldstein, 1995; Ferguson et al., 2002;
Gerbal-Chaloin et al., 2002; Chen et al., 2005).
Many drugs and foreign compounds are metabolized in the
liver to electrophilic and reactive metabolites (Chang et al.,
1997; Erve, 2006; Guengerich, 2006; Takakusa et al., 2008).
Moreover, xenobiotics capable of undergoing redox cycling
induce oxidative stress by generation of semiquinone radicals
and reactive oxygen species. The effects of electrophilic me-
tabolites and oxidative stress on the regulation of the human
CYP2C genes have not yet been investigated. The alteration of
cellular redox state by reactive intermediates activates tran-
scription factors such as activator protein 1 (AP-1) and nuclear
factor E2-related factor 2 (Nrf2). AP-1 factors are basic leucine
zipper proteins that regulate the transcription of target genes in
response to environmental stimuli as either homodimers of the
Jun family (cJun, JunD, and JunB) proteins or heterodimers of
the Jun and Fos family proteins (cFos, FosB, Fra1, and Fra2)
(Eferl and Wagner, 2003). The dimeric AP-1 proteins bind to
a cis-acting 12-O-tetradecanoylphorbol 13-acetate–responsive
element on the promoter of target genes. AP-1 proteins also
form transcriptionally active heterodimers with Nrf2, which
binds to the antioxidant or electrophilic response element
(Hayes et al., 2010). The transcriptional activity of AP-1 and
Nrf2 is also regulated by phosphorylation via the mitogen-
activated protein kinase (MAPK) signaling pathways (Mendelson
et al., 1996; Ventura et al., 2003; Sherratt et al., 2004).
We identified two putative AP-1 sites (TGAGTCA) inCYP2C9
promoter at positions 22201 and 21930, which are highly con-
served in the promoter of the CYP2C19 gene. In this study, we
show that the CYP2C9 and CYP2C19 genes are induced by the
electrophilic xenobiotic tert-butylhydroquinone (tBHQ) in cul-
tured human hepatocytes, and we examined the mechanism of
this induction using the CYP2C9 promoter. We demonstrate
that the pathway for CYP2C9 gene induction by electrophiles
involves an AP-1 heterodimer of cFos and JunD. We show for
the first time using chromosome conformation capture (3C)
assays the formation of a DNA loop on the CYP2C9 promoter
possibly allowing formation of a complex between cFos bound to
the distal site and JunD to the proximal AP-1 site. Thus, drugs
and environmental chemicals capable of inducing oxidative
stress enhance the expression of CYP2C9 by this mechanism.
Materials and Methods
Chemicals and Reagents. t-BHQ, SP600125 [Jun N-terminal
kinase (JNK inhibitor)], and PD98059 [mitogen-activated protein
kinase kinase (MEK) inhibitor] were purchased from Sigma-Aldrich
(St. Louis, MO). Anti–glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) antibody (clone 6C5, MAB374) was purchased from
Millipore (Temecula, CA). Rabbit polyclonal antibodies against c-Jun
(sc-44), JunD (329; sc-74), JunB (N-17; sc-46), c-Fos (sc-52), Nrf2 (C-20;
sc-722), Activating transcription factor 2 (ATF2) (C-19; sc-187), and
ATF4 (C-20; sc-200) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Phospho-JunD (Ser100) antibody (9164), stress-
activated protein kinase/JNK antibody (9252), phospho–stress-
activated protein kinase/JNK (Thr183/Tyr185) antibody (9251), p42
MAPK [extracellular signal-regulated kinase (ERK2)] antibody (9108),
and phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) antibody (9101)
were obtained from Cell Signaling Technology (Danvers, MA). The
expression plasmids for c-Fos (pRSV-cfos) and c-Jun (pRSV-cjun) were
provided by C. B. Pickett and T. Nguyen (Schering-Plough Research
Institute, Kenilworth, NJ). The expression plasmids for JunD
(pcDNA3.1-JunD) and JunB (pcDNA3.1-JunB) were gifts of S. K.
Agarwal (Genetics and Endocrinology Section, National Institute of
Diabetes and Digestive and Kidney Diseases, National Institutes of
Health). The Nrf2 expression plasmid (pCI-Nrf2neo) was provided by
K. S. Ramos (University of Louisville, Louisville, KY).
Isolation and Culture of Human Hepatocytes. One set of
human livers was obtained from kidney transplant donors at the
Transplantation and Surgical Clinic, Semmelweis University Budapest
(Budapest, Hungary). Permission from the Hungarian Regional Commit-
tee of Science and Research Ethics was obtained to use human tissues.
Clinical histories of the donors are shown in Table 1. Liver cells were
isolated by themethod of Bayliss andSkett (1996), as previously described
(Belic et al., 2009). Hepatocytes having viability better than 90% as
determined by trypan blue exclusion were used in the experiments. The
cells were plated at a density of 1.7  105 cells/cm2 in collagen-precoated
plastic dishes in the previously described medium (Ferrini et al., 1998).
After overnight attachment, the medium was replaced with serum-free
medium. Twenty-four hours after serum deprivation, cells were exposed
to tBHQ (50 mM) or rifampicin (5 mM) for 24 and 48 hours, and specific
mRNAs for CYP2C9, CYP2C19, and CYP2A6 were measured, as de-
scribed below. The control cultures received the same volume of the
vehicle [dimethylsulfoxide (DMSO)] as the treated cultures.
RNA Isolation andQuantitative Real-Time Polymerase Chain
Reaction. Total RNA was isolated from human primary hepatocytes
and HepG2 cells using TRIzol reagent (Invitrogen, Carlsbad, CA) and
RNeasy mini kit (Qiagen, Valencia, CA), respectively, according to the
manufacturer’s instructions, and reverse transcribed to cDNA using the
SuperScript III First Strand Synthesis System for reverse-transcription
polymerase chain reaction (PCR) kit (Invitrogen) with oligo(dT) primers.
Quantitative real-time polymerase chain reaction was performed using
the ABI Prism 7900 Sequence Detector System (Applied Biosystems,
Foster City, CA) with the following primers and probe sets purchased
from Applied Biosystems: CYP2C9 (Hs00426397_m1), CYP2C19
(Hs00426380_m1), and GAPDH (Hs03929097_g1). Each cDNA (100
ng) was mixed with 1 TaqMan Universal PCR master mix (Applied
Biosystems). All quantitative real-time PCR experiments were per-
formed in triplicate with cDNA samples from independent samples, as
described previously (Makia et al., 2012). mRNA levels were normalized
with GAPDH as the endogenous control.
Preparation of Microsomes. Additional cultured human pri-
mary hepatocytes in six-well plates were obtained from Triangle
Research Laboratories (Research Triangle Park, NC) for immuno-
blotting experiments with CYP2C proteins before and after treatment
with tBHQ or DMSO controls. Microsomes were prepared from cultured
human hepatocytes, as follows. Cells were suspended in ice-cold buffer
(0.1 M potassium phosphate, pH 7.4, containing 0.25 M sucrose and
1 mM EDTA) and homogenized using a Potter-Elvehjem homogenizer.
The 10,000g supernatant was subjected to ultracentrifugation for
2 hours at 112,000g using a TLA-55 rotor (Beckman Coulter, Palo Alto,
CA). The microsomal pellet was resuspended in 50 mM potassium
phosphate buffer (pH 7.4) containing 20% glycerol and 1mMEDTA, and
stored at 280°C for later use.
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Western Blotting. Total cell and nuclear extracts were prepared
from HepG2 cells, as described previously (Makia et al., 2012). The
extracts were separated on 4–20% SDS-PAGE gels and transferred
onto nitrocellulose membranes. Membranes were probed with anti-
bodies against GAPDH (1:5000) as the endogenous control or 1:1000
dilutions of all other primary antibodies. Horseradish peroxidase–
conjugated goat anti-rabbit or anti-mouse secondary (1:10,000) anti-
bodies were used, and the proteins were visualized using SuperSignal
West Pico or Dura Western blotting detection system (Thermo
Scientific, Rockford, IL). Microsomal proteins were separated using
a Protean II xi Cell (Bio-Rad), and Western blot was performed with
the following rabbit antibodies: 1590 (raised to recombinant purified
CYP2C9 expressed in Escherichia coli, which recognizes CYP2C9 .
CYP2C19. .CYP2C8), 1592 (raised to recombinant purified CYP2C9
expressed in E. coli, which recognizes CYP2C9 . .CYP2C19 and
CYP2C8), and 1937 (specific anti-CYP2C8 peptide antibody that
recognizes only CYP2C8) (Zhang et al., 2012). The following CYP2C
standards were also used: human liver microsomes (Gentest, Woburn,
MA) and yeast CYP2C9, CYP2C8, and CYP2C19.
Small Interfering RNA Transfection. Silencer Select Prede-
signed small interfering RNA (siRNA) for JunD (s7664), Jun (s7658),
and negative control 1 (negative control) were purchased fromAmbion
(Austin, TX). HepG2 cells cultured in six-well plates were transfected
with 50 pmol/well siRNA duplexes using Lipofectamine 2000 (Life
Technologies, Carlsbad, CA) for 48 hours. Total cell extracts were
prepared for Western blot analysis.
Transcription Factor Binding Site Analysis. The Genomatrix
MatInspector software was used to analyze the human CYP2C9
(23077/11) and CYP2C19 (24722/11) promoters for putative Nrf2
(TGACNNNGCA) and AP-1 (TGAC/GTCA) binding sites.
Site-Directed Mutagenesis. A QuikChange II XL site-directed
mutagenesis kit (Stratagene, La Jolla, CA) was used to mutate the
putative AP-1 binding sites located at positions 22201 and 21930 of
the human CYP2C9 promoter, according to the manufacturer’s in-
structions. The primers for mutagenesis of the putative AP-1 sites were
as follows: 22201 (forward, 59-TGATACTTTGTCTCACTTGGTTGA-
TAATTGCTCATTTCT-39 and reverse, 59-AGAAATGAGCAAT-
TATCAACCAAGTGAGACAAAGTATCA-39); 21930 (forward, 59-
TGTTAGAGTTTAGAGTTTCATTGGTTGGGGACCAAGTTATTGC-39
and reverse, 59-GCAATAACTTGGTCCCCAACCAATGAAACTCTAAAC
TCTAACA-39). The mutated sites are underlined. The mutation of the
putative AP-1 sites was confirmed by sequencing.
Transfection of HepG2 Cells and Luciferase Reporter Assays.
The human hepatocellular carcinoma cell line, HepG2 (HB8065;
American Type Culture Collection, Rockville, MD), was maintained in
modified Eagle’s media supplemented with 10% fetal bovine serum
(HyClone, Logan UT), 1 mM sodium pyruvate, 2 mM glutamine, and
penicillin-streptomycin (Life Technologies). Cells were seeded in 24-
well plates and transfected with 200 ng/well CYP2C9 luciferase
construct and 20 ng Renilla luciferase plasmid using Lipofectamine
2000. The cells were cotransfected with pRSV-cFos (50 ng), pRSV-cJun
(50 ng), pcDNA3.1-JunD (100 ng), and pCI-Nrf2neo (100 ng) plasmids.
The cells were resuspended in passive lysis buffer (Promega, Madison,
WI), and luciferase activity was assayed with a Dual-Glo luciferase
reporter assay system. The data were expressed relative to Renilla
luciferase activity to normalize for transfection efficiency. Transfection
experiments were performed in triplicate and repeated at least twice for
confirmation.
Electrophoretic Mobility Shift Assays. Nuclear extracts were
prepared from HepG2 cells, as described previously (Makia et al., 2012).
The sequences of the complementary oligonucleotides were as follows:
AP-1 control (forward, 59-CGCTTGATGAGTCAGCCGGAA-39and reverse,
59-TTCCGGCTGACTCATCAAGCG-39); distalCYP2C9AP-1 site (forward,
59-GTGATACTTTGTCTCACTGAGTCAATAATTGCTCATTTCT-39 and
reverse, 59-AGAAATGAGCAATTATTGACTCAGTGAGACAAAGTAT-
CAC-39); and proximal CYP2C9 AP-1 site (forward, 59-GAGTTTA-
GAGTTTCATGAGTCAGGGACCAAGTTATTGCT-39 and reverse,
59-AGCAATAACTTGGTCCCTGACTCATGAAACTCTAAACTC-39). The
complementary oligonucleotides (1 pmol/ml) were annealed by incubating
at 95°C for 5 minutes with annealing buffer (10 mM Tris-HCl, 1 mM
EDTA, and 50mMNaCl, pH 8.0). Double-stranded oligonucleotides were
labeled with [g-32P]ATP using a T4 polynucleotide kinase kit following
the supplier’s instructions (Promega). Unincorporated nucleotides were
removed by chromatography onmicrospin G-25 columns (GEHealthcare,
Piscataway, NJ). Protein-DNA complexes were formed by incubating
5mg nuclear proteins and 106 cpm of 32P-labeled oligonucleotide probe for
30 minutes at room temperature in a total volume of 20 ml with binding
buffer [10 mM Tris-HCl, 1 mM EDTA, 1 mMMgCl2, 10% glycerol, 1 mM
DTT, and 50 ng/ml poly(dI-dC)]. Binding specificity was assessed by
addition of 100-fold excess of unlabeled double-stranded oligonucleotides.
For supershift analyses, antibodies (4 mg) were added to the binding
reactions after the initial 20-minute incubation, and incubation was
continued for 2 hours at 4°C. Loading buffer was added to the reactions,
and 10 ml binding reactions were resolved by electrophoresis on 5%
polyacrylamide gels using 0.5 Tris/borate/EDTA buffer (50 mM Tris,
pH 8.3, 50mMsodiumborate, and 1mMEDTA) at 200V for 2 hours. The
gel was transferred to Whatman 3MM filter paper, dried, and exposed to
film overnight at 280°C.
In Vitro Transcription/Translation of cFos and cJun Pro-
teins and Electrophoretic Mobility Shift Assays with the Pure
Translated Proteins. cFos and cJun proteins were synthesized in
vitro from 1mg pRSV-cFos, pCMV-cFos, or pCR2.1-cJun plasmids using
a TNT Quick Coupled Transcription/Translation System (Promega)
in the presence of unlabeled or labeled 35S-methionine, following the
manufacturer’s instructions. Additional controls containing the TNT
Quick master mix with no template DNA were also performed. The
labeled proteins were separated on a 4–20% Tris-glycine polyacryl-
amide gel. The gel was dried on a sheet of Whatman 3MM filter paper,
and the protein bands were visualized by autoradiography. In vitro
translation of unlabeled cFos and cJun proteins was verified by
Western blotting using antibodies against cFos and cJun. Electropho-
reticmobility shift assay (EMSAs) were performed by incubating 5ml in
vitro translated unlabeled cFos or cJun proteins with labeled double-
stranded oligonucleotides containing AP-1 control, CYP2C9 distal and
proximal AP-1 sites. EMSAs with the in vitro transcribed proteins were
performed essentially as described above.
Chromatin Immunoprecipitation Assay. Chromatin immuno-
precipitation (ChIP) assays were performed, as described previously
(Makia et al., 2012), using theMAGnify Chromatin-Immunoprecipitation
System (Life Technologies), according to the manufacturer’s protocol,
TABLE 1
Clinical histories of human donors
Donor Age (year) Sex Cause of Death Medication Smoking/Alcohol
HH-167 44 Female Stroke Noradrenaline No/No
HH-172 44 Male Cerebral
hemorrhage
Dopamine Casual smoker/No
HH-173 62 Female Subarachnoidal
hemorrhage
Noradrenaline No/No
HH-179 47 Female Stroke Mannitol,
Noradrenaline
No/No
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with minor modifications. Briefly, HepG2 cells in 10-cm dishes treated
with either DMSO (control) or tBHQ (50 mM) were fixed in 1%
formaldehyde at room temperature for 10 minutes to cross-link the
nuclear proteins to DNA, and the reaction was stopped by incubation
with 125 mM glycine for 10 minutes. Cells were resuspended in lysis
buffer (10mMTris-HCl, 10 mMNaCl, 0.5%Nonidet P-40) containing 1
complete protease inhibitor (Roche Diagnostics, Indianapolis, IN) and
incubated on ice for 30 minutes. The nuclei were harvested and
solubilized in buffer containing 50 mM Tris-Cl (pH 8.0), 1% SDS,
10 mM EDTA, and 0.5 mM phenylmethanesulfonyl fluoride with 1
complete protease inhibitor. The homogenate was sonicated on ice at 40%
setting (Branson Sonicator, North Olmsted, OH) to shear the chromo-
somal DNA into fragments of ∼200–500 bp in size. Immunoprecipitation
of the sonicatedDNA fragmentswas performed overnight at 4°Cwith 4mg
antibodies against IgG (negative control), JunD, c-Fos, cJun, or
phospho-JunD conjugated to Dynabeads protein A/G. The cross-
linked protein-DNA complexes were uncross-linked in the presence of
proteinase K, and the purified DNA was analyzed by PCR using PCR
SuperMix High Fidelity (Life Technologies) with primers spanning the
putative distal (position 22201) and proximal (position 21930) AP-1
sites in the promoter of CYP2C9 gene. The sequences of the primers
were as follows: distal AP-1 site (forward, 59-GAATGGCATGAACCCAG-
GAGCTGGA-39and reverse, 59-AAGAAATGAGCAATTATTGACTCAG-39);
proximal AP-1 site (forward, 59-ACAGCAACCGAGCTTATTTTACCCA-39
and reverse, 59-ACAGCCCCAGTTGACTAGATTGAGA-39). PCR prod-
ucts were resolved on a 1.5% agarose gel and visualized by ethidium
bromide staining.
In Vitro and In Vivo 3C Assays. In vitro 3C assays were
performed essentially as previously described with minor modifica-
tions (Babu et al., 2008; Inoue and Negishi, 2009; Li et al., 2010).
Nuclear extracts (100 mg) prepared fromHepG2 cells transfected with
empty vector or cFos expression vector were incubated with 50 ng
linearized CYP2C9 plasmid (containing 23077 to 11 of the CYP2C9
promoter) at room temperature for 45 minutes. The protein-DNA
complexes were cross-linked by fixing with 1% formaldehyde for 10
minutes. The cross-linking reaction was quenched with 0.125 M
glycine for 10 minutes. After overnight ethanol precipitation at 220°C,
complexes were digested with 10 U BsrGI (New England Biolabs,
Ipswich, MA) at 37°C for 2 hours. BsrGI enzyme activity was
inactivated by incubation at 80°C for 20 minutes. Ligation was
performed with 20 ng DNA using 800 cohesive end units of T4 DNA
ligase (NewEngland Biolabs) at 16°C for 4 hours. SDS (1%) was added
to the ligation reaction, 0.3 M NaCl to reverse cross-link the protein-
DNA complexes, and the reaction was incubated overnight at 65°C.
Proteinase K (200 mg/ml) was added to the reaction mixture, which
was incubated at 55°C for 1 hour. DNA was purified using a PCR
purification kit (Qiagen) and amplified with PCR SuperMix High
Fidelity kit for the looped and control DNA products. The sequences of
the primers spanning the ligated and control regions were as follows:
looped product (97 bp: forward, 59-TACTAGACTGAATTACGAAAT-39
and reverse, 59-AACATTGACGCATCATCATCA-39); control product
(194 bp: forward, 59-ACAGCAACCGAGCTTATTTTACCCA-39 and re-
verse, 59-ACAGCCCCAGTTGACTAGATTGAGA-39).
In vivo 3C was performed, as previously described (Hagege et al.,
2007). Briefly, human hepatocytes were treated with 1% formalde-
hyde for 10 minutes to cross-link protein-DNA, and the cross-linking
reaction was stopped by incubation with 0.125 M glycine for 10
minutes. Cells were harvested and resuspended in lysis buffer (10mM
Tris-HCl, 10 mM NaCl, 0.2% Nonidet P-40) containing 1 complete
protease inhibitor (Roche Diagnostics). The nuclei were washed with
1 New England Biolabs buffer 2 and incubated in 1 New England
Biolabs buffer 2 containing 0.3% SDS at 37°C for 1 hour. SDS in the
reaction was sequestered by incubation with 1.8% Triton X-100 at 37°C
for 1 hour. Chromatin (∼20 mg) was digested with 200 U BsrG1 by
incubation at 37°C for 2 hours, and enzyme activity was inactivated
by incubation with 1.6% SDS at 65°C for 20 minutes. The digested
chromatin (3 mg) was incubated at 37°C for 1 hour with 1 T4 ligase
buffer and 1% Triton X-100. Two thousand units of T4 DNA ligase
were added, and the reaction was incubated at 16°C for 4 hours. The
protein-DNA complexes were reverse cross-linked by overnight
incubation with 100 mg/ml proteinase K at 65°C. RNA was digested
by addition of 25 mg/ml RNase A, and the reaction was incubated at
37°C for 30 minutes. The DNA was purified by phenol-chloroform
extraction using phenol:chloroform:isoamyl alcohol (25:24:1) and
ethanol precipitated. The purified DNA was amplified for the looped
and control DNA products by conventional PCR. The in vivo 3C
primer sequences for amplification of the looped product were 144 bp:
forward, 59-ACCTCTCAATCTAGTCAACTG-39 and reverse, 59-CAAC-
CAAAGCTCATAGTTTAT-39, and for control product, 194 bp: forward,
59-ACAGCAACCGAGCTTATTTTACCCA-39 and reverse, 59-ACAGCCC-
CAGTTGACTAGATTGAGA-39.
Statistical Analysis. Datawere analyzedwith Student’s t tests or
one-way analysis of variance (ANOVA), followed by Tukey’s test using
Sigma Stat software (Sigma Stat 3.5; SPSS, San Jose, CA). Differ-
ences were considered to be statistically significant at P value 0.05.
Results
tBHQ Induces CYP2C9 and CYP2C19 in Primary
Human Hepatocytes. We examined the effect of treatment
with 50 mM electrophilic tBHQ on CYP2C9, CYP2C19, and
CYP2A6 mRNA expression in primary human hepatocytes
after 24 and 48 hours (Fig. 1A, 1B). Maximum induction of
CYP2A6, CYP2C9, and CYP2C19 mRNA by 50 mM tBHQ
(∼4.0-, 3.0-, and 2.5-fold, respectively) occurred at 48 hours
(Fig. 1B). As expected, CYP2C9, CYP2C19, and CYP2A6
mRNAs were also induced by the PXR agonist, rifampicin
(Fig. 1A, 1B). CYP2A6 has been reported to be induced via both
PXR and electrophilic activation (Abu-Bakar et al., 2013).
Treatment of primary hepatocytes with tBHQ also induced
expression of CYP2C9 and CYP2C19 proteins (∼2.5-fold and
∼fivefold, respectively) after 48 hours but did not induce
CYP2C8 protein (Fig. 1C, 1D). The slightly higher induction of
CYP2C19 may partially reflect its low constitutive levels.
Functional Characterization of the Putative AP-1
Binding Sites inCYP2C9Promoter Constructs inHepG2
Cells. Computer analysis of CYP2C9 gene promoter revealed
the presence of two putative AP-1 sites (TGAGTCA) at
positions 22201 and 21930. These AP-1 sites are highly
conserved between the CYP2C9 and CYP2C19 promoters but
were not found in the CYP2C8 promoter (Fig. 2A). Site-
directed mutagenesis was used to investigate the relative
importance of the two putative AP-1 sites in the transactivation
of the CYP2C9 promoter by tBHQ.Mutation of either AP-1 site
significantly decreased CYP2C9 luciferase activity in HepG2
cells treated with tBHQ compared with the wild-type plasmid.
Double mutation of both the distal and proximal AP-1 sites
abolished CYP2C9 reporter activation by tBHQ (Fig. 2B).
These results demonstrate that both AP-1 sites are required
for maximal activation of the CYP2C9 luciferase promoter
construct by tBHQ.
Effect of AP-1 Transcription Factors on the Expres-
sion of CYP2C9 in HepG2 Cells. We next examined the
effect of ectopic expression of AP-1 proteins and Nrf2 on
CYP2C9 luciferase reporter activity in HepG2 cells (Fig. 3A).
Ectopic overexpression of Nrf2 had no significant effect on
CYP2C9 luciferase activity. We observed ∼30-, ∼6.7-, and
∼sevenfold increases in CYP2C9 luciferase activity after trans-
fection with cFos, cJun, and JunD, respectively. Ectopic ex-
pression of cFos together with cJun resulted in significantly
lower CYP2C9 luciferase activity compared with cFos alone.
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Similar levels of CYP2C9 luciferase activity were observed
when cells were transfected with cFos and JunD (∼30-fold)
compared with cFos alone. Because Fos proteins are not known
to form active transcriptional complexes as a homodimer, but
form active heterodimers with Jun proteins, we examined the
levels of Jun and ATF proteins in nuclear extracts of HepG2
cells before and after ectopic expression of cFos (Fig. 3B).
Western blot analysis of nuclear extracts showed high basal
levels of JunD, cJun, ATF2, andATF4 in contrast to low levels of
cFos and JunB. Due to high basal level of JunD and cJun in the
nuclear extract of HepG2 cells, we hypothesize that CYP2C9
might be induced by formation of an AP-1 heterodimer of cFos
and JunD. The absence of synergism after ectopic expression of
cFos and JunD could be due to the high levels of constitutive
expression of JunD. Therefore, we examined the effect of si-
lencing either JunD or cJun on cFos-induced transactivation
of CYP2C9 luciferase activity in HepG2 cells. Western blot
analysis confirmed silencing of JunD (86% knockdown) and
cJun (70% knockdown) proteins by JunD- and cJun-specific
siRNA, respectively, compared with control siRNA (Fig. 3C,
3D). As predicted, knockdown of JunD significantly decreased
cFos-mediated transactivation of CYP2C9 luciferase activity
(Fig. 3E), suggesting that both cFos and JunD contribute to
the induction of CYP2C9 gene. The residual increase in lucif-
erase activation presumably reflects the small amounts of JunD
or another transcription factor present after silencing JunD (Fig.
3D). In contrast, silencing of cJun had no significant effect on
cFos activation of CYP2C9 luciferase reporter activity (Fig. 3E).
Induction and Phosphorylation of AP-1 Proteins in
HepG2 Cells Treated with tBHQ. The activation by AP-1
protein usually involves increases in AP-1 mRNA and protein
levels as well as increases in phosphorylation of AP-1 proteins
and their DNA-binding activities. We examined the effects of
50 mM tBHQ inHepG2 cells on cFos protein after 1- to 12-hour
treatment. cFos was dramatically increased as early as 1 hour
after tBHQ treatment and maximally after 4 hours (Fig. 4A).
We also observed a dramatic increase in phosphorylation of
JunD 1 hour after tBHQ treatment with themaximal increase
occurring at 4 hours. Alterations in the cellular redox state are
known to activate ERK and JNK, which then phosphorylate
and activate AP-1 proteins (Eferl andWagner, 2003). Dramatic
increases in phosphorylation of JNK and ERK were present
1 hour after tBHQ treatment (Fig. 4B). Treatment with
PD98059 (a specific MEK inhibitor) inhibited tBHQ-induced
Fig. 1. Human CYP2C mRNA and protein levels were induced by tBHQ in primary human hepatocytes. Induction of CYP2C9, CYP2C19, and CYP2A6
mRNA in primary human hepatocytes following treatment with 50 mM tBHQ for 24 hours (A) and 48 hours (B). Results are presented relative to
uninduced cells. A PXR inducer, rifampicin (5 mM), was used as a positive control. *P , 0.05, significantly different compared with DMSO control
(Student’s t test); **P = 0.06 compared with DMSO control (Student’s t test). (C)Western blot analysis showed CYP2C9 and CYP2C19 protein levels were
induced in human primary hepatocytes after treatment with 50 mM tBHQ for 48 hours, whereas CYP2C8 levels were unchanged. (D) Densitometry
analysis of Western blot with Image J software. *P , 0.05, significantly different compared with DMSO control (Student’s t test). The following
recombinant yeast CYP2C protein controls were used: 2C9 (CYP2C9), 2C8 (CYP2C8), and 2C19 (CYP2C19). HLM, human liver microsomes (Gentest).
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ERK phosphorylation and cFos expression, whereas SP600125
(a JNK inhibitor) inhibited JunD phosphorylation (Fig. 4C).
Moreover, the inhibition of ERK and JNK phosphorylation by
PD98059 and SP600125 significantly decreased the tBHQ-
mediated induction of CYP2C9 mRNA (Fig. 4D), suggesting
that tBHQ-induced expression of CYP2C9 mRNA involves
activation of ERK and JNK, which induce expression of cFos
expression and phosphorylation of JunD, respectively.
EMSA Analysis of Putative AP-1 Binding Sites. EMSA
was used to examine whether the AP-1 proteins bind to the
CYP2C9 distal and proximal AP-1 sites. 32P-labeled oligonu-
cleotides containing the consensus AP-1 element (Promega,
Madison, WI), CYP2C9 distal, and proximal AP-1 sites were
incubated with nuclear extracts from both untreated and
tBHQ-treated HepG2 cells (Fig. 5A–C). We observed formation
of a DNA-protein complex with the labeled AP-1 consensus
oligonucleotides, which was effectively inhibited by addition of
excess unlabeled oligonucleotide (cold), indicating the binding
was specific (Fig. 5A). Supershift experiments showed that the
protein complexes formed with the distal and proximal CYP2C9
AP-1 oligonucleotides were shifted by antibodies against cFos
and JunD, respectively, in tBHQ-treated nuclear extracts but
not detectable in control nuclear extracts. Although cJun did
not supershift CYP2C9 proximal or distal AP-1 site in EMSAs
(Fig. 5B, 5C), the cJun antibody produced a consistent de-
pletion of the DNA-protein complex at the proximal site in
complexes with tBHQ nuclear extracts (Fig. 5B, 5C), suggest-
ing the possibility of minimal binding at these sites. Supershift
experiments were performed by incubating radiolabeled oligo-
nucleotides containing CYP2C9 distal, proximal AP-1 sites,
and AP-1 consensus element with tBHQ-treated HepG2 cell
nuclear extracts and with broad-spectrum AP-1 antibodies or
Nrf2 proteins (Fig. 5D–F). Again the complexes were super-
shifted by antibodies against cFos (for the distal site) and
JunD (for proximal site), indicating that cFos interacts with
the distal and JunD with the proximal site after incubation
with tBHQ-treated nuclei (Fig. 5D, 5E). The DNA-protein
complexes with the labeled AP-1 consensus oligonucleotide
were competed with excess unlabeled oligonucleotide (Fig. 5F,
lane 3), and complexes were supershifted by antibodies against
cFos, JunD, and, importantly, cJun (lanes 4–6), indicating the
presence of these proteins in the AP-1 complex. These results
indicate that, in contrast to the AP-1 consensus control, cFos
distinctly binds to the distal site and JunD to the proximal site
of CYP2C9. Because the DNA-protein complexes at the prox-
imal site were decreased by antibody to cJun, we cannot rule
out cJun binding. However, these EMSAs contrast with the
AP-1 consensus sequence, where a distinct supershift is seen
with the same antibody for cJun.
EMSAs Using In Vitro Translated cFos or cJun with
the Proximal and Distal CYP2C9 AP-1 Sites and the AP-1
Consensus Site. cFos and cJun synthesized using a TNT
Quick Coupled Transcription/Translation System in the
presence of 35S-methionine or unlabeled methionine were
verified by autoradiography and Western blot using anti-
bodies to cJun and cFos (Supplemental Fig. 1). To determine
whether either cFos or cJun binds to the AP-1 sites ofCYP2C9,
EMSAs were performed using both sites as well as the AP-1
consensus control. Pure translated cFos bound to the distal
(22201) AP-1 site ofCYP2C9 either as amonomer or homodimer
Fig. 2. Effect of mutagenesis of the putative proximal and distal AP-1 elements on induction of CYP2C9 promoter luciferase activity after treatment of
HepG2 cells with tBHQ. (A) Computer analysis of the CYP2C9 promoter showed two putative AP-1 sites (TGAGTCA) at positions 22201 and 21930,
which are highly conserved in CYP2C19. (B) HepG2 cells were transiently transfected with p2C9-3.0Luc (2C9-WT), 2C9-Dis (mutation of distal AP-1
site), 2C9-Pro (mutation of proximal AP-1 site), or 2C9-DM (mutation of both distal and proximal AP-1 site). Twenty-four hours after transfection, cells
were treated with either DMSO (0.1%) or tBHQ (50 mM) for 24 hours. Cells were harvested, and firefly and Renilla luciferase activities were measured.
Results were expressed as fold induction compared with DMSO-treated cells. *P , 0.05, significantly different compared with tBHQ-treated 2C9-WT
(wild-type)-transfected cells (one-way ANOVA, followed by Tukey’s test).
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in the absence of other AP-1 proteins (Supplemental Fig.
2A). In contrast, we found no evidence for binding of in vitro
translated cJun to the proximal 21930 CYP2C9 AP-1 site
(or the distal site), although it did bind to the AP-1
consensus control (Supplemental Fig. 2B).
ChIP Analysis of Transcription Factor Binding to
the Putative TREs in HepG2 Cells before and after
Treatment with tBHQ. ChIP experiments were also used to
assess in vivo recruitment of cFos and JunD to the distal and
proximal AP-1 sites before and after treatment of HepG2 cells
with tBHQ. As shown in Fig. 5G, we observed enhanced
recruitment of JunD and phospho-JunD to the proximal AP-1
site after treatment of the HepG2 cells with tBHQ compared
with more moderate recruitment of cFos. There was minimal re-
cruitment of JunD and cFos without treatment of the cells
with tBHQ and no recruitment of phospho-JunD. The proximal
and distal AP-1 sites appeared to bind JunD moderately even
in the absence of tBHQ. However, JunD is highly expressed in
these cells. Moreover, it should be noted that the distal and
proximal sites are only ∼270 bases apart, and the average
length of the sonicated fragments is 200–500 bp. Thus, we
cannot completely separate the sites. cFos bound to both the
distal and proximal sites only after treatment of the cells with
tBHQ. Binding to both sites is expected by an in vivo method
such as ChIP if the distal and proximal AP-1 sites are brought
together by DNA looping as proposed. This is probable because,
in ChIP experiments, formaldehyde is used to cross-link the
protein to DNA prior to sonication. The binding to both sites
may also reflect the incomplete separation of the sites. Binding
of cJun was not detected at either site before or after tBHQ
treatment.
3C Analysis of DNA Looping. Because CYP2C9 tran-
scription may be induced by a cFos and JunD heterodimer, we
propose that DNA looping could bring the distal and proximal
AP-1 sites into close proximity, allowing formation of an AP-1
complex containing cFos and JunD. To test this hypothesis, we
Fig. 3. CYP2C9 luciferase activity is significantly transactivated by ectopic expression of c-Fos. (A) Cotransfection of cJun with cFos, but not JunD,
decreased the cFos-mediated increase in CYP2C9 luciferase activity. HepG2 cells were cotransfected with p2C9-3.0Luc (spanning 23077 to +1 of the
CYP2C9 promoter) and various expression plasmids, as indicated. Cells were harvested after 48 hours, and luciferase activity was normalized to Renilla
luciferase activity. Results were expressed as fold induction from at least three independent experiments compared with that of vector control. *P, 0.05,
significantly different compared with vector control; †P , 0.05, significantly different compared with cFos-transfected cells (one-way ANOVA, followed
by Tukey’s test). (B) Western blot analysis of AP-1 proteins (40 mg) in nuclear extracts of vector control and c-Fos plasmid-transfected HepG2 cells using
antibodies against c-Fos, c-Jun, JunB, JunD, ATF2, and ATF4. (C) Western blot analysis of JunD and cJun in total HepG2 cell extracts after transfection
with control siRNA (siControl), JunD-specific siRNA (siJunD), or cJun-specific siRNA (sicJun). (D) Densitometry analysis of the Western blot of JunD
and cJun knockdown, as shown in (C), using Image J software. (E) Knockdown of JunD, but not cJun, significantly decreased cFos-mediated
transactivation of CYP2C9 luciferase activity. HepG2 cells were transfected with p2C9-3.0Luc reporter plasmid and expression plasmid for cFos
together with the indicated siRNAs for 48 hours. Luciferase activity was normalized to Renilla luciferase, and results were expressed as fold induction
from at least three independent experiments compared with that of control siRNA-transfected cells. *P , 0.05, significantly different compared with
vector-transfected cells; †P , 0.05, significantly different compared with cFos/siControl-transfected cells (one-way ANOVA, followed by Tukey’s test).
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assessed the interaction between these two AP-1 sites by 3C
assays in HepG2 cells after ectopic expression of cFos. The
promoter region of CYP2C9 contains BsrG1 restriction sites
that closely flank the distal and proximal AP-1 sites (Fig. 6A).
Fig. 6B shows a graphical representation of the 3C method
explained in Materials and Methods similar to the strategy
described by Dekker (2006). The purified DNA was amplified
by conventional PCR with primers spanning the ligated
region to produce the looped product and control primers for
linear DNA product. We showed increased formation of looped
product after ectopic cFos expression compared with empty
vector control (Fig. 7A). The digestion with EcoRV was used to
differentiate looping from end-to-end ligation. Because there is
the possibility of end-to-end ligation instead of DNA looping,
the linearized plasmid was incubated with cFos-transfected
nuclear extracts and digested with either BsrGI or both BsrGI
and EcoRV. The increased formation of looped product after
ectopic cFos expression was eliminated with EcoRV digestion
(Fig. 7B), indicating the formation of predominantly looped
product instead of end-to-end ligation product. The formation of
the looped product was significantly reduced by mutation of
both AP-1 sites compared with wild-type sequence (Fig. 7C).
In vivo 3C experiments were also performed in primary
human hepatocytes transfected with control siRNA or JunD-
specific siRNA and treated with DMSO or tBHQ.We observed
∼fourfold increase in the formation of looped product by tBHQ
in control siRNA-transfected cells by PCR (Fig. 8A). The
increased formation of looped products by tBHQ in control
hepatocytes was significantly reduced by knockdown of JunD.
Consistent with the in vitro 3C, increased looped product
formation by tBHQ in cultured hepatocytes was absent when
DNAwas digested with both BsrGI and EcoRV compared with
BsrGI alone (Fig. 8B), indicating the formation of predomi-
nantly looped product instead of end-to-end ligation product.
The induction of CYP2C9 mRNA levels by tBHQ in primary
human hepatocytes was significantly decreased by knock-
down of JunD (Fig. 8C). Consistent with experiments in HepG2
cells, the specific inhibitors of ERK (PD98059) and JNK
(SP600125) significantly decreased the tBHQ-mediated
induction of CYP2C9 mRNA (Fig. 8D).
Discussion
In this study, we report a new mechanism for CYP2C9 and
CYP2C19 induction, but not CYP2C8, by electrophiles and
oxidative stress. Many drugs and environmental compounds,
such as butylated hydroxyanisole, are metabolized in the liver
to electrophilic or reactive metabolites with enhanced pro-
duction of reactive oxygen species and induction of oxidative
stress (Chang et al., 1997; Erve, 2006; Guengerich, 2006;
Takakusa et al., 2008). The role of electrophiles and oxidative
stress in the regulation of the CYP2C genes has received very
little attention. Reactive intermediates are important signal-
ing molecules that induce the expression of cytoprotective
genes by directly activating redox-sensitive transcription
factors or indirectly activating kinase signaling pathways
(Mendelson et al., 1996; Yu et al., 1997; Takakusa et al., 2008).
Our laboratories previously reported the regulation of the
electrophile detoxification gene, Aldh1a1, by electrophiles
such as acrolein and tBHQ in mouse liver and liver-derived
cell lines (Makia et al., 2012).
Fig. 4. ERK and JNK are essential for
tBHQ-mediated induction of CYP2C9
mRNA by increased expression of cFos
and phosphorylation of JunD. (A) Treat-
ment of HepG2 cells with tBHQ (50 mM)
increased expression of cFos and phos-
phorylation of JunD. HepG2 cells were
treated with tBHQ for various time
intervals (0–12 hours). Total cell lysates
were analyzed by Western blot analysis
with antibodies against cFos, phospho-
JunD, and JunDwithGAPDHas a loading
control. (B) The activation of ERK and
JNK by tBHQ. Membranes were probed
with antibodies against phospho-p54/46
JNK, p54/46 JNK, phospho-p44/42 ERK,
and p42 ERK. (C) Increased cFos expres-
sion and JunD phosphorylation were
inhibited by PD98059 (MEK inhibitor)
and SP600125 (JNK inhibitor), respec-
tively. HepG2 cells were pretreated for 2
hours with 20 mM PD98059 or 50 mM
SP600125 and then treated with 50 mM
tBHQ for 6 hours. Total cell extracts were
analyzed by Western blot with antibodies
against phospho-ERK, phospho-JunD,
JunD, and GAPDH. (D) Cells were pre-
treated with 20 mM PD98059 and 50 mM
SP600125 for 2 hours, and then treated
with 50 mM tBHQ for 24 hours and
CYP2C9 mRNA analyzed by quantitative
real-time PCR. *P , 0.05, significantly
different compared with DMSO-treated
cells; †P , 0.05, significantly different
compared with tBHQ-treated cells (one-
way ANOVA, followed by Tukey’s test).
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Due to the presence of putative AP-1 sites (TGAGTCA) at
positions 22201 and 21930 in the promoter of CYP2C9 and
the knowledge that many inducers of CYP2C are capable of
forming reactive intermediates, we hypothesized that drugs
and xenobiotics capable of inducing oxidative stress may
enhance CYP2C9 expression by activation of AP-1 and/or
possibly Nrf2 proteins. We show that both CYP2C9 and
CYP2C19 genes were induced by tBHQ in cultured human
hepatocytes. tBHQ is a cytochrome P450-dependent metabo-
lite of BHA that undergoes autoxidation to tert-butylquinone,
Fig. 5. EMSA analysis indicates formation of a nuclear protein complex with the distal (22201) and proximal (21930) AP-1 sites of the CYP2C9
promoter, and ChIP analysis confirms the binding of cFos and JunD in vivo. (A) 32P-labeled double-stranded oligonucleotides containing CYP2C9 distal
AP-1 site, CYP2C9 proximal AP-1 site, and AP-1 consensus sequence (as a positive control) were incubated for 30 minutes with 5 mg nuclear extracts
from control (NE) or tBHQ-treated (tBQNE) cells. In competition experiments, a 100-fold excess of unlabeled double-stranded oligonucleotide inhibited
formation of the complex. (B) 32P-labeled double-stranded oligonucleotides containing CYP2C9 distal AP-1 site and (C) CYP2C9 proximal AP-1 site were
incubated for 30 minutes with 5 mg nuclear extracts isolated from DMSO (0.1%)- or tBHQ (50 mM)-treated HepG2 cells. Supershift experiments were
then performed by incubating the binding reactions with 4 mg antibodies to cFos, cJun, JunD, or JunB for 2 hours at 4°C. (D–F) 32P-labeled
oligonucleotides containing the CYP2C9 distal AP-1 site (D), CYP2C9 proximal AP-1 site (E), or AP-1 consensus sequence (F) (as a positive control) were
incubated for 30 minutes with 5 mg nuclear extracts from tBHQ-treated HepG2 cells, and supershift experiments were performed by incubating the
binding reactions with 4 mg antibodies to a wider spectrum of AP-1 antibodies (cFos, cJun, JunD, JunB, ATF2, ATF4) or Nrf2 antibodies for 2 hours at 4°C.
(G) ChIP analysis showed binding of cFos and JunD in vivo to the CYP2C9 distal and proximal AP-1 sites. Chromatin was prepared from the HepG2 cells
treated with DMSO control or tBHQ for 24 hours; sheared; immunoprecipitated with IgG (negative control), cFos, cJun, JunD, or phospho-JunD (P-JunD)
antibodies conjugated to Dynabeads protein A/G; and analyzed by PCR with primers spanning the distal and proximal AP-1 sites.
Regulation of CYP2C9 by AP-1 Activation and DNA Looping 133
generating reactive oxygen species by redox cycling. The pro-
oxidant activity of tBHQ was supported by experiments that
demonstrated that HepG2 cells treated with tBHQ generated
hydroxyl radicals and resulted in decreased levels of in-
tracellular glutathione (Pinkus et al., 1996). Moreover, the
induction of GST-Ya expression and AP-1 activity by tBHQ
was inhibited by exogenous catalase and the antioxidant,
N-acetyl cysteine (Pinkus et al., 1996).
AP-1 transcription factors regulate target gene expression
as either homodimers of Jun family proteins or heterodimers
of the Jun and Fos family proteins (Eferl and Wagner, 2003).
Previously, Fos proteins had not been shown to form active
Fig. 6. Schematic diagram of the 3C assay. (A) The CYP2C9 promoter showing the distal and proximal AP-1 sites with restriction enzymes, BsrGI and
EcoRV, for the 3C assay. (B) Outline of the 3Cmethod. For in vitro 3C assays, linearized plasmid (23077 to +1) containing both AP-1 sites were incubated
with nuclear extracts. For in vivo 3C, primary human hepatocytes were directly treated with formaldehyde to cross-link protein to DNA. The restriction
enzyme, BsrGI, digested the DNA close to the AP-1 sites. The digested DNAwas then ligated with or without T4 DNA ligase. The protein-DNA complexes
were reversed cross-linked, and the control and ligated DNAwere purified using either a PCR purification kit (in vitro 3C) or phenol chloroform (in vivo 3C).
The purified DNA was amplified by conventional PCR with primers spanning the ligated region (primers A and B) for looped products and control primers
(primers C and D) for linear DNA products. The digestion with EcoRV was used to differentiate looping from end-to-end ligation.
Fig. 7. In vitro 3C assays demonstrating interaction of the CYP2C9 distal and proximal AP-1 binding sites by DNA looping. (A) The linearized CYP2C9
promoter (23077 to +1) was incubated with nuclear extract (NE) from HepG2 cells before or after transfection with cFos (cFosNE). In vitro 3C assays
were performed with BsrGI, and the purified DNA was amplified with primers spanning the ligated region compared with products amplified with
internal control primers. Below is a densitometry analysis with Image J software. *P, 0.05, significantly different compared with nuclear extract from
HepG2 cells (Student’s t test). 2L, absence of ligase; +L, ligase. (B) Confirmation of DNA looping by EcoRV restriction analysis. The CYP2C9 promoter
(23077 to +1) was incubated with nuclear extract from cFos-transfected HepG2 (cFosNE). The cross-linked DNA was digested with BsrGI alone or with
BsrGI and EcoRV restriction enzymes. The reversed cross-linked and purified DNA was amplified with primers spanning the ligated region. *P , 0.05,
significantly different compared with BsrG1/EcoRV digestion in the absence of nuclear extracts; †P, 0.05, significantly different compared with BsrG1
digestion in the presence of cFos-transfected nuclear extracts (one-way ANOVA, followed by Tukey’s test). (C) Wild-type CYP2C9 promoter (WT) or the
promoter containing mutated distal and proximal AP-1 sites (DM) was incubated with nuclear extract from cFos-transfected cells (cFosNE). In vitro 3C
assays were performed, as described inMaterials and Methods. *P , 0.05, significantly different from ligated CYP2C9WT promoter (Student’s t test).
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transcriptional complexes as homodimers. However, in this
study and another study by one of our laboratories, we find
that translated cFos can bind to the distal site as either
a homodimer or a monomer (Xu et al., 2014). We showed that
tBHQ-induced expression of CYP2C9 is mediated possibly by
interaction between cFos and JunD on different AP-1 sites.
Additive effects of ectopic cFos and JunD were not observed in
induction of CYP2C9 mRNA or CYP2C9-luciferase activity
probably due to the high levels of constitutive expression of
JunD in HepG2 cells. However, silencing JunD strongly
suggested that CYP2C9-luciferase activity is transactivated
by a cFos and JunD heterodimer. Until recently, JunD was
thought to form a transcriptionally inactive complex with
cFos, but an active heterodimer with FosB (Byun et al., 2006).
Fig. 8. In vivo 3C assay to assess interaction of the distal and proximal AP-1 sites by DNA looping in primary human hepatocytes. (A) Hepatocytes were
transfected with either control siRNA or JunD-specific siRNA. Forty-eight hours after transfection, cells were treated with DMSO (control) or tBHQ for
24 hours. Cells were treated with formaldehyde to cross-link protein-DNA. In vivo 3C assays were performed with BsrGI restriction enzyme, and the
purified DNA was amplified with primers spanning the ligated region for looped PCR product and internal control primers for control products. Below is
a densitometry analysis of the in vivo 3C with Image J software. *P , 0.05, significantly different compared with ligated tBHQ/siControl-transfected
cells (one-way ANOVA, followed by Tukey’s test). (B) Confirmation of DNA looping by EcoRV restriction analysis. Primary human hepatocytes were
treated with DMSO control or tBHQ for 24 hours. The formaldehyde cross-linked DNA was digested with BsrGI alone or with BsrGI and EcoRV. The
reversed cross-linked and purified DNAwas amplified with primers spanning the ligated region. *P, 0.05, significantly different compared with BsrG1-
digested tBHQ-treated primary human hepatocytes (one-way ANOVA, followed by Tukey’s test). (C) Primary human hepatocytes transfected with either
control siRNA or JunD-specific siRNA were treated with DMSO (control) or tBHQ for 24 hours, and (D) primary human hepatocytes were pretreated
with 20 mM PD98059 and 50 mM SP600125 for 2 hours, and then treated with 50 mM tBHQ for 24 hours, and CYP2C9 mRNA levels were analyzed by
quantitative real-time polymerase chain reaction. *P, 0.05, significantly different compared with DMSO-treated cells; †P, 0.05, significantly different
compared with tBHQ-treated cells (one-way ANOVA, followed by Tukey’s test).
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However, Dong and coworkers provided evidence that hema-
topoietic genes were induced by a transcriptionally active
heterodimer of cFos and JunD (Lee et al., 2012). Ectopic
expression of Nrf2 had no significant effect on CYP2C9-
promoter luciferase activity alone or in combination with
cJun. Electrophilic or extracellular stresses are known to
activate MAPK consisting of p38, ERK, and JNK (Mendelson
et al., 1996; Yu et al., 1997; Cui et al., 2010). AP-1 proteins are
major targets of activated MAPK. Activated MAPK pathways
regulate AP-1 transcriptional activity by altering gene expres-
sion, phosphorylation, and DNA-binding activity. Previous
studies have demonstrated that the activation of JunD is
mediated by enhanced phosphorylation of Ser100 at the
N terminus by JNK and ERK (Gallo et al., 2002; Yazgan and
Pfarr, 2002; Tsuji, 2005). This phosphorylation site also con-
served in cJun (Ser73) is detected using phospho-Ser73 antibody
in Western blot experiments. Although both ERK and JNK
pathways were activated by tBHQ, we showed that increased
phosphorylation of JunD by tBHQ was mediated by JNK.
Previous experiments demonstrate increased cFos expression
is mediated by activated ERK, which phosphorylates and
activates ternary complex factors (Eferl and Wagner, 2003).
Activated ternary complex factor binds to the serum response
element in the promoter of fos, resulting in increased expression.
We showed that tBHQ-induced expression of cFos was regulated
by ERK activation. To assess the relevance of JNK and ERK
signaling pathways in tBHQ-mediated increase in CYP2C9
expression, selective kinase inhibitors were used. PD98059,
a selective inhibitor of MEK1, inhibits the phosphorylation of
ERK1/2, whereas SP600125, a specific inhibitor of JNK, inhibits
the phosphorylation and activation of JunD. The incubation of
cells with these inhibitors attenuates cFos expression and JunD
phosphorylation by tBHQ and resulted in significant attenua-
tion of tBHQ induction of CYP2C9 mRNA, suggesting major
roles of ERK and JNK in induction of CYP2C9 by tBHQ.
DNA looping is a mechanism that can bring cis-response
elements with their bound proteins in close proximity to each
other or even distal regulatory elements into close proximity
with the transcription start site to activate transcription by
direct or indirect interaction between transcription factors. In
the present study, we demonstrate that the distal and
proximal AP-1 sites in CYP2C9 promoter are brought in close
proximity by DNA looping, possibly allowing formation of
a complex containing cFos at the distal AP-1 site and JunD at
the proximal AP-1 site.
Although this is the first report to describe the formation of
a DNA loopmediated by two AP-1 sites on a target cytochrome
P450 gene promoter, previous studies described the formation
of short DNA looping of other gene promoters mediated by
AP-1 and other transcription factors such as nuclear factor kB
(NF-kB). DNA looping created by interactions between the
NF-kB and AP-1 binding site of osteopontin promoter
synergistically transactivates the osteopontin gene in murine
macrophages (Zhao et al., 2011). The interaction between
cJun at 21069 and NF-kB p65 at 286 mediated by DNA
looping on the inducible nitric oxide synthase promoter was
shown to be responsible for initiation of iNOS transcription in
lipopolysaccharide-stimulated ANA-1 murine macrophages
(Guo et al., 2008). It is known that interaction between factors
bound at nonadjacent cis-acting elements can induce bending
or looping of the DNA to form higher order structures
(Matthews, 1992; Kerppola and Curran, 1993; Natesan and
Gilman, 1993). Indeed, the transcription factors ATF and
NF-kB have been shown to induce bending or looping of DNA
on the E-selectin promoter (Meacock et al., 1994). We have
demonstrated the pivotal role of cFos and JunD in looping of
theCYP2C9 promoter to possibly allow formation of a complex
containing these proteins. Overexpression of cFos enhanced
looping, whereas knockdown of JunD decreased the formation
of loop product. We also show that both the distal and
proximal AP-1 sites are involved in CYP2C9 looping. DNA
loop formation was confirmed by the absence of looped product
after EcoRV digestion. We propose that DNA looping brings the
distal and proximal AP-1 sites into close proximity, possibly
leading to interaction between cFos and JunD for induction of
CYP2C9 gene.
A proposed model for the regulation of CYP2C9 by tBHQ is
illustrated in Fig. 9. The induction of CYP2C9 expression
by the pro-oxidant, tBHQ, is mediated by cFos/JunD hetero-
dimers. ERK and JNK are essential for tBHQ-mediated
induction of CYP2C9 expression. Activation of ERK by tBHQ
induces cFos expression, whereas JNK activation stimulates
JunD phosphorylation. The cFos and JunD distinctly bind
to the distal (22201) and proximal (21930) AP-1 sites, re-
spectively, in EMSAs. Both AP-1 sites are brought together by
DNA looping, as shown by 3C assay, for successful induction
of CYP2C9 by tBHQ. These results provide strong evidence
that compounds capable of inducing oxidative stress enhance
the expression of CYP2C9 and represent an additional mech-
anism for induction of CYP2C9 and CYP2C19, thus altering
the clearance of substrates metabolized by these enzymes.
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